Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Russell Hull

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Thrombosis Journal|January 1, 2020
Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patientsBenjamin Brenner, Roopen Arya, Jan Beyer-Westendorf, et al.
American Heart Journal|December 16, 2014
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendmentAlexander T Cohen, Robert Harrington, Samuel Z Goldhaber, et al.
Journal of Thrombosis and Thrombolysis|September 8, 2019
Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trialWalter Ageno, Renato D Lopes, Megan K Yee, et al.
American Heart Journal|March 1, 2014
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) studyAlexander T Cohen, Robert Harrington, Samuel Z Goldhaber, et al.
Archives of Internal Medicine|October 24, 2002
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulantCharles Marc Samama, Muriel Vray, Jeanne Barré, et al.
AJR. American Journal of Roentgenology|October 24, 2007
CT venography and compression sonography are diagnostically equivalent: data from PIOPED IILawrence R Goodman, Paul D Stein, Fadi Matta, et al.
Journal of Thrombosis and Thrombolysis|March 2, 2011
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolAlexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, et al.
The New England Journal of Medicine|February 8, 2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patientsAlexander T Cohen, Theodore E Spiro, Harry R Büller, et al.
American Heart Journal|June 20, 2017
When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trialsC Michael Gibson, Samuel Z Goldhaber, Alexander T Cohen, et al.
Circulation|June 28, 2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failureAlexandre Mebazaa, Theodore E Spiro, Harry R Büller, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Thrombosis Journal|January 1, 2020
Evaluation of unmet clinical needs in prophylaxis and treatment of venous thromboembolism in at-risk patient groups: pregnancy, elderly and obese patientsBenjamin Brenner, Roopen Arya, Jan Beyer-Westendorf, et al.
American Heart Journal|December 16, 2014
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendmentAlexander T Cohen, Robert Harrington, Samuel Z Goldhaber, et al.
Journal of Thrombosis and Thrombolysis|September 8, 2019
Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trialWalter Ageno, Renato D Lopes, Megan K Yee, et al.
American Heart Journal|March 1, 2014
The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) studyAlexander T Cohen, Robert Harrington, Samuel Z Goldhaber, et al.
Archives of Internal Medicine|October 24, 2002
Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulantCharles Marc Samama, Muriel Vray, Jeanne Barré, et al.
AJR. American Journal of Roentgenology|October 24, 2007
CT venography and compression sonography are diagnostically equivalent: data from PIOPED IILawrence R Goodman, Paul D Stein, Fadi Matta, et al.
Journal of Thrombosis and Thrombolysis|March 2, 2011
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolAlexander Thomas Cohen, Theodore Erich Spiro, Harry Roger Büller, et al.
The New England Journal of Medicine|February 8, 2013
Rivaroxaban for thromboprophylaxis in acutely ill medical patientsAlexander T Cohen, Theodore E Spiro, Harry R Büller, et al.
American Heart Journal|June 20, 2017
When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trialsC Michael Gibson, Samuel Z Goldhaber, Alexander T Cohen, et al.
Circulation|June 28, 2014
Predicting the risk of venous thromboembolism in patients hospitalized with heart failureAlexandre Mebazaa, Theodore E Spiro, Harry R Büller, et al.
Pageof 3